CAR-37 mediated tumor clearance of MCL patient-derived xenograft. (A) Protocol schema: NSG mice were injected intravenously with 1 × 106 MCL patient-derived cells and monitored for tumor burden by bioluminescent imaging (BLI) over time. At day 0, mice were randomly assigned on the basis of tumor burden to receive 3 × 106 control T cells (UTD), CAR-37, or CAR-19. (B) Representative BLI of MCL xenografts over time. (C) Average flux (photons/s) of whole mice in the 3 groups at different points. Graph is representative 2 simultaneous experiments of 5 mice per group, conducted with CAR T cells obtained from 2 different healthy donors, and pooled data. Mean ± SD shown (Student t test, *P < .05). (D) Absolute numbers of CAR T cells were monitored in peripheral blood using flow cytometry. Absolute counts of CAR T cells are plotted at day 14.